AR063942A1 - HEPATITIS C VIRUS PROTEASA INHIBITING OXYMYL COMPOUNDS - Google Patents

HEPATITIS C VIRUS PROTEASA INHIBITING OXYMYL COMPOUNDS

Info

Publication number
AR063942A1
AR063942A1 ARP070102426A ARP070102426A AR063942A1 AR 063942 A1 AR063942 A1 AR 063942A1 AR P070102426 A ARP070102426 A AR P070102426A AR P070102426 A ARP070102426 A AR P070102426A AR 063942 A1 AR063942 A1 AR 063942A1
Authority
AR
Argentina
Prior art keywords
compounds
hepatitis
virus
oxymyl
proteasa
Prior art date
Application number
ARP070102426A
Other languages
Spanish (es)
Inventor
Sun Ying
Yat Sun Or
Wang Zhe
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063942(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of AR063942A1 publication Critical patent/AR063942A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de formula (1) o sus sales aceptables para uso farmacéutico, ésteres o prodrogas que inhiben la actividad de la serina proteasa, particularmente la actividad del virus de la hepatitis C (HCV) NS3-NS4A. Son utiles como agentes antivirales. Composiciones farmacéuticas que comprenden los compuestos mencionados y métodos para tratar una infeccion por HCV en un sujeto administrando una composicion farmacéutica que comprende tales compuestos.Compounds of formula (1) or their salts acceptable for pharmaceutical use, esters or prodrugs that inhibit the activity of serine protease, particularly the activity of hepatitis C virus (HCV) NS3-NS4A. They are useful as antiviral agents. Pharmaceutical compositions comprising the aforementioned compounds and methods for treating an HCV infection in a subject by administering a pharmaceutical composition comprising such compounds.

ARP070102426A 2006-06-06 2007-06-06 HEPATITIS C VIRUS PROTEASA INHIBITING OXYMYL COMPOUNDS AR063942A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81146406P 2006-06-06 2006-06-06
US50338506A 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
AR063942A1 true AR063942A1 (en) 2009-03-04

Family

ID=38832101

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102426A AR063942A1 (en) 2006-06-06 2007-06-06 HEPATITIS C VIRUS PROTEASA INHIBITING OXYMYL COMPOUNDS

Country Status (5)

Country Link
AR (1) AR063942A1 (en)
CL (1) CL2007001630A1 (en)
TW (1) TW200815481A (en)
UY (1) UY30391A1 (en)
WO (1) WO2007146695A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8426360B2 (en) 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8268777B2 (en) 2007-12-05 2012-09-18 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
WO2009076166A2 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Oximyl hcv serine protease inhibitors
EP2224920A4 (en) 2007-12-06 2012-05-09 Enanta Pharm Inc Process for making macrocyclic oximyl hepatitis c protease inhibitors
JP2011506472A (en) 2007-12-14 2011-03-03 エナンタ ファーマシューティカルズ インコーポレイテッド Macrocyclic oxymil hepatitis C serine protease inhibitor
WO2009085978A1 (en) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
JP5490778B2 (en) 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Fluorinated macrocycles as hepatitis C virus inhibitors
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
JP6239597B2 (en) 2012-05-15 2017-11-29 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Drug conjugate, conjugation method and use thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
DK3472149T3 (en) 2016-06-21 2023-11-27 Orion Ophthalmology LLC HETEROCYCLIC PROLINE MID DERIVATIVES
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
CN110904121B (en) * 2019-12-17 2022-11-29 南京农业大学 Application of susceptibility gene SR30 in improving crop resistance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors

Also Published As

Publication number Publication date
CL2007001630A1 (en) 2008-02-08
TW200815481A (en) 2008-04-01
WO2007146695A1 (en) 2007-12-21
UY30391A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
AR063942A1 (en) HEPATITIS C VIRUS PROTEASA INHIBITING OXYMYL COMPOUNDS
AR061238A1 (en) HEPATITIS C PROTEASE INHIBITORS MACROCICLIC OXYLMYL COMPOUNDS
DOP2019000218A (en) INHIBITORS OF MACROCYCLIC PROLINES DERIVED HCV SERINE PROTEASES
ECSP077649A (en) PIRIDAZINONILOS MACROCICLICOS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C
ECSP077648A (en) MACROCICLIC TETRAZOLILS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C
UY30437A1 (en) QUINOXALINIL MACROCECLIC INHIBITORS OF SERINE PROTEASE VIRUS OF HEPATITIS C
ECSP10010254A (en) COMPOUNDS CONTAINING QUINOXALINE AS INHIBITORS OF THE HEPATITIS C VIRUS
CO2020002980A2 (en) Antiviral agents against hepatitis b.
CO6571891A2 (en) Hepatitis C virus inhibitors
UY37998A (en) ANTIVIRAL AGENTS AGAINST HEPATITIS B
ECSP088258A (en) SERINA PROTEASAS INHIBITORS
UY33183A (en) INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
UY32462A (en) NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT
UY32793A (en) INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS AND ITS USES
CL2011000589A1 (en) Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.
CL2011002830A1 (en) Compounds derived from haloalkyl heteroaryl benzamides; pharmaceutical composition use of the composition in the treatment of a viral infection, such as hepatitis b and c virus.
DOP2013000238A (en) DERIVATIVES OF NUCLEOSIDS 2'-SUBSTITUTES AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES
EA200970805A1 (en) SERINPROTEAS INHIBITORS FOR THE TREATMENT OF HCV INFECTIONS
SV2009003281A (en) ESPIRO KETONA ACETIL-COA CARBOXILASA.0 INHIBITORS.
ECSP15035530A (en) TETRAYCLIC COMPOUNDS SUBSTITUTED WITH HETEROCICLO AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES
AR054347A1 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
MX2010006518A (en) Macrocyclic oximyl hepatitis c serine protease inhibitors.
CU20090058A7 (en) PIRAZOLINE COMPOUNDS AND THEIR USE AND PHARMACEUTICAL COMPOSITIONS
GT200600161A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
ECSP13012791A (en) INHIBITORS OF SERINE PROTEASE OF HEPATITIS C BASED ON MACROCYCLES OF FENANTRIDINE

Legal Events

Date Code Title Description
FB Suspension of granting procedure